Print Page | Sign In | Join ISSX
ISSX Workshop: Translation of in vitro ADMET Science to in vivo: Current Perspectives and Challenges
Tell a Friend About This EventTell a Friend
 

ISSX will host a workshop in 2021 entitled, Translation of in vitro ADMET Science to in vivo: Current Perspectives and Challenges.

 Export to Your Calendar 2/16/2021 to 2/19/2021
When: February 16 - 19, 2021
9:00 AM
Where: Virtual
Contact: ISSX
202-367-1160

« Go to Upcoming Event List  

Please join us for an exciting virtual workshop jointly sponsored by ISSX and the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) in February 2021. The workshop title is ‘Translation of in vitro ADMET Science to in vivo: Current Perspectives and Challenges’ and will bring together scientists from academia, industry and regulatory agencies in an interactive format to discuss contemporary topics in applied small molecule enzyme and transporter research.  We are planning sessions covering not only laboratory and analytical challenges associated with studying enzymes and transporters in vitro, but also issues involved in the translation of in vitro ADMET data to clinical drug-drug interactions (DDIs). There will be a mixture of presentations, including rapid-fire talks, along with roundtable discussion sessions that we hope will allow for the exchange of perspectives and ideas across in regulatory, academic and industrial spaces to help address drug development challenges and enable future research into experimental and model-based approaches for biotransformation enzymes and transporters. 

Watch for more details on this workshop, including registration and program details, coming soon!

Workshop Organizing Chairs:
Chris Gibson, Merck Research Laboratories, West Point, PA, USA and Lei Zhang, Silver Spring, MD, USA

Workshop Organizing Committee:

  • Adrian Fretland, AstraZeneca, Waltham, MA, USA
  • Aleksandra Galetin, University of Manchester, United Kingdom
  • Yurong Lai, Gilead Sciences, Foster City, CA, USA
  • Laurent Salphati, Genentech Inc., South San Francisco, CA, USA   
  • Kimio Tohyama, Takeda Pharmaceuticals, Cambridge, MA, USA
  • Jashvant Unadkat, University of Washington, Seattle, WA, USA